» Articles » PMID: 37261295

Inverse Association of Serum Osteocalcin and Bone Mineral Density in Renal Transplant Recipients

Overview
Journal Tzu Chi Med J
Specialty General Medicine
Date 2023 Jun 1
PMID 37261295
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Osteocalcin, a protein from osteoblasts, affects bone mineralization and turnover. This study evaluates the association between fasting serum osteocalcin and bone mineral density (BMD) in renal transplant recipients.

Materials And Methods: This study recruited 66 renal transplant recipients. We analyzed blood biochemistry studies from fasting blood samples. The serum osteocalcin levels were measured using a commercial enzyme immunoassay kit. We measure BMD by dual-energy X-ray absorptiometry in lumbar vertebrae (L2-L4). By the World Health Organization classification, we group recipients into three groups: normal, osteopenia, and osteoporosis.

Results: Of the renal transplant recipients, 8 patients (12.1%) were osteoporosis, and 28 patients (42.4%) were osteopenia. From normal to osteoporosis groups, the osteoporosis group has highest serum osteocalcin ( < 0.001), alkaline phosphatase ( = 0.005), lowest body mass index ( = 0.015), and body weight ( = 0.008). Females had lower lumbar BMD than males among recruited renal transplant recipients ( = 0.023). In the multivariate forward stepwise linear regression analysis, body weight (adjusted change = 0.138; = 0.010), and logarithmically transformed osteocalcin (log-osteocalcin; adjusted R change = 0.131; = 0.012) can predict lumbar BMD in the renal transplant recipients.

Conclusion: Our study showed that fasting serum osteocalcin concentration was negatively correlated with the lumbar BMD in renal transplant recipients.

Citing Articles

A diagnostic approach integrated multimodal radiomics with machine learning models based on lumbar spine CT and X-ray for osteoporosis.

Liwei Cheng , Cai F, Xu M, Liu P, Liao J, Zong S J Bone Miner Metab. 2023; 41(6):877-889.

PMID: 37898574 DOI: 10.1007/s00774-023-01469-0.

References
1.
Coen G, Mazzaferro S, Bonucci E, Taggi F, Ballanti P, Bianchi A . Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up. Kidney Int. 1985; 28(5):783-90. DOI: 10.1038/ki.1985.198. View

2.
Bonnin M, Gonzalez M, Grino J, Cruzado J, Bover J, Martinez J . Changes in serum osteocalcin levels in the follow-up of kidney transplantation. Ann Clin Biochem. 1997; 34 ( Pt 6):651-5. DOI: 10.1177/000456329703400609. View

3.
Kyd P, Vooght K, KERKHOFF F, Thomas E, Fairney A . Clinical usefulness of bone alkaline phosphatase in osteoporosis. Ann Clin Biochem. 1998; 35 ( Pt 6):717-25. DOI: 10.1177/000456329803500603. View

4.
Lee M, Lee C, Shih M, Ho G, Chen Y, Hsu B . N-terminal pro-B-type natriuretic peptide is inversely related to bone mineral density in renal transplant recipients. Transplant Proc. 2014; 46(10):3443-7. DOI: 10.1016/j.transproceed.2014.06.077. View

5.
Jagtap V, Ganu J, Nagane N . BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women. Indian J Clin Biochem. 2012; 26(1):70-3. PMC: 3068775. DOI: 10.1007/s12291-010-0074-2. View